Videos

Naomi Dempsey, MD, discusses her poster presented at the 2023 San Antonio Breast Cancer Symposium analyzing the correlation of the Breast Cancer Index and patient risk factors.

Comprehensive insights on clinical trial data that have led to further development of sacituzumab govitecan for patients with non–small cell lung cancer.

The TAR-200 treatment has demonstrated a favorable safety profile in clinical trial, with primarily low-grade irritated voiding symptoms that are manageable and expected with intravesical therapy, without concerning systemic side effects, making it a promising new option to delay or reduce radical cystectomy in patients with BCG-unresponsive NMIBC.

The TAR-200 treatment for BCG-unresponsive NMIBC works through a catheter-placed intravesical device that elutes gemcitabine over 3 weeks, providing a high complete response rate of 77% in early testing, likely due to the sustained release mechanism.

Senthil Damodaran, MD, PhD, discusses data from a phase 2 trial of futibatinib in patients with metastatic HR-positive/HER2-negative breast cancer with FGFR1 amplifications.

Anthony Hunter, MD, closes his discussion by sharing advice for clinicians treating patients with myelofibrosis.

Dr Anthony Hunter reviews the other three approved JAK inhibitors for treatment of myelofibrosis: ruxolitinib, fedratinib, and pacritinib.

Jeremy Abramson, MD, discusses what the findings from the phase 3 TRANSFORM study of lisocabtagene maraleucel mean for patients with relapsed large B-cell lymphoma.

Benjamin Garmezy, MD, discusses some of the ongoing challenges or disparities seen in the community oncologist setting related to clinical trials.

Experts on non–small cell lung cancer discuss the role of antibody-drug conjugates and review their mechanism of action.

A review of preclinical studies looking at TROP2 expression in patients with non–small cell lung cancer.

Mwanasha Merrill discusses results from a phase 2 study which evaluated PD-1 blockade post autologous stem cell transplantation with pembrolizumab in patients with peripheral T-cell lymphoma.

BCG-unresponsive NMIBC treatment aims to eradicate disease or prolong disease-free intervals, with radical cystectomy as gold standard; newer options like pembrolizumab and gemcitabine/docetaxel provide improved alternatives, though logistic challenges remain.

BCG-unresponsive non-muscle invasive bladder cancer risks invasive progression; providers should suspect disease based on any abnormalities in cystoscopy and cytology, not just voiding symptoms.

Joshua K. Sabari, MD, offers key takeaways on treating patients with EGFR+ non–small cell lung cancer, highlighting the safety profile.

Expert insights on the treatment of patients with non–small cell lung cancer positive for EGFR mutations and what the PAPILLON study seeks to address.

An expert on EGFR+ non–small cell lung cancer discusses factors that influence treatment decisions.

An overview of recent data from the MARIPOSA trial investigating amivantamab plus lazertinib in patients with EGFR-positive advanced lung cancer.

Joshua K. Sabari, MD, reviews clinical trial data from FLAURA2 on osimertinib plus chemotherapy in patients with EGFR-mutated advanced lung cancer.

A medical oncologist provides an overview of treatment options available for patients with EGFR+ non–small cell lung cancer.

Joshua K. Sabari, MD, reviews the patient profile of a 73-year-old patient with EGFR+ non–small cell lung cancer.

Francis P. Worden, MD, provides background on the COSMIC-311 study, highlighting the methods and design utilized.

Hussein Tawbi, MD, PhD, closes his discussion by sharing some clinical pearls for fellow oncologists treating patients with metastatic melanoma.

Hussein Tawbi, MD, PhD, explains that if a patient with metastatic melanoma and a BRAF mutation progresses after initial checkpoint inhibitors, either combination immunotherapy or MEK inhibitor therapy is considered, based on disease progression pace and pattern.

The SIMPLIFY-1 trial investigated the use of momelotinib in JAK inhibitor-naive patients with myelofibrosis, primarily symptomatic with spleen enlargement, hepatomegaly, or anemia; results showed momelotinib led to improved transfusion independence, reduced transfusion burden, and decreased anemia compared to ruxolitinib.

Anthony Hunter, MD, explains that anemia is a common complication in patients with myelofibrosis, often worsening over time; treatment strategies involve monitoring, transfusion support, and considering additional anemia-directed agents.

Mark Agulnik, MD, discusses advances in determining the molecular drivers of the tumor in the sarcoma space.

Mrinal M. Gounder, MD, delves into the data supporting the recent FDA approval of nirogacestat for the treatment of adult patients with desmoid tumors.

Liza C. Villaruz, MD, discusses what research in the EGFR-positive lung cancer space has recently caught the attention of experts.

Mohamad Adham Salkeni, MD, FRCPC, discusses the mechanism of action of ivaltinostat and what rationalizes its use in combination with capecitabine for patients with metastatic pancreatic adenocarcinoma.